OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) Files An 8-K Regulation FD Disclosure

Item7.01.

Starting on January9, 2017, representatives of Orexigen
Therapeutics, Inc. (the Company or Orexigen) will be presenting
to and conducting meetings with investors, analysts and others.
During these presentations and meetings, the Company will present
the slides attached as Exhibit 99.1 to this Current Report on
Form 8-K, which is incorporated herein by reference.

The information in this Item7.01 of this Current Report on Form
8-K, including Exhibit 99.1, is being furnished to Item7.01 and
shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that section, and it
shall not be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or under the Exchange
Act, whether made before or after the date hereof, except as
expressly set forth by specific reference in such filing to this
item of this report.

***

By filing this Current Report on Form 8-K and furnishing this
information, the Company makes no admission as to the materiality
of any information in this report. The information contained in
this report is intended to be considered in the context of the
Companys filings with the Securities and Exchange Commission
(SEC) and other public announcements that the Company makes, by
press release or otherwise, from time to time. The Company
undertakes no duty or obligation to publicly update or revise the
information contained in this report, although it may do so from
time to time as its management believes is appropriate. Any such
updating may be made through the filing of other reports or
documents with the SEC, through press releases or through other
public disclosure.

Orexigen cautions you that statements included in this report
that are not a description of historical facts are
forward-looking statements. Words such as believes, anticipates,
plans, expects, indicates, will, should, intends, potential,
suggests, assuming, designed and similar expressions are intended
to identify forward-looking statements. These statements are
based on Orexigens current beliefs and expectations. These
forward-looking statements include statements regarding: the
potential success of marketing and commercialization of Contrave
in the United States, including the recently-launched
patient-focused marketing campaign; the potential for Contrave
and Mysimba to achieve commercial success globally; the potential
for Orexigen and its partners to obtain regulatory approvals for
Contrave and Mysimba in additional markets outside the United
States; the ability of Orexigen to enter into successful
partnership arrangements for Contrave/Mysimba in additional
territories outside the United States; the potential for Orexigen
to achieve commercial success for Contrave in the United States
without a partner; the sales force capacity, effectiveness and
efficiency for commercialization of Contrave in the United
States; the Companys strategic plans and initiatives; Orexigens
ability to manage its expenses, including by implementing a CVOT
that achieves significant cost savings; the potential to acquire,
develop and market additional product candidates or approved
products; Orexigens preclinical development plans and ability to
perform IND-enabling studies successfully; and on-going patent
litigation related to Contrave. The inclusion of financial
modeling, forward-looking statements and
potential transaction plans and terms should not be regarded as a
representation by Orexigen that any of its plans will be
achieved. Actual results may differ materially from those
expressed or implied in this presentation due to the risk and
uncertainties inherent in the Orexigen business, including,
without limitation: the potential that the marketing and
commercialization of Contrave/Mysimba will not be successful,
particularly, with respect to Contrave, in the U.S. following the
launch of the patient-focused marketing campaign; the Companys
ability to obtain and maintain partnerships and marketing
authorization globally; our ability to adequately inform
consumers about Contrave; our ability to successfully
commercialize Contrave with a specialty sales force in the United
States; our ability to successfully complete the post-marketing
requirement studies for Contrave; the capabilities and